BioSpace News Archive

SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) announced that it has received approval from Health Canada to proceed with enrollment of volunteers in Phase III trials following earlier positive Phase II results for its Nitric Oxide Nasal Spray (NONS) for the prevention and early treatment of COVID-19 and its variants.

Mercaptor Discoveries (Mercaptor) today advanced their therapeutic candidate to treat brain-inflammation found in patients with long COVID, also known as post-acute sequelae of COVID-19

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY ® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults

Entera Bio Ltd. announced the final 6-month bone mineral density (BMD) results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis.

Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), and AGC Biologics, today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH).

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A (“Kedrion”) has exercised its option to acquire the remainder of the Company’s plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion.

Jaguar Health, Inc. announced that Jaguar is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell.

Theratechnologies Inc. today announced the appointment of Mr. Frank Holler as a new independent member to its Board of Directors.

Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced the appointment of Celia Economides as executive vice president and chief financial officer.